摘要
利钠肽(BNP)和N末端B型利钠肽原(NT-proBNP)被广泛用于心衰的筛查、诊断,继而经过干预,预防心衰的发生,它是心衰的生物标志物。对于心衰患者,出院前的利钠肽监测有助于评估患者出院后的心血管事件风险。对于其他多种心血管疾病,包括急性冠脉综合征,心房颤动等,也均会导致利钠肽水平增高。因此,BNP和NT-proBNP作为标记物,在临床上将是一个活跃的研究领域。
Natriuretic peptide(BNP)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)are widely used in the screening and diagnosis of heart failure,and then through intervention,to prevent the occurrence of heart failure,it is a biomarker of heart failure.In patients with heart failure,natriuretic peptide monitoring before discharge is helpful in assessing the risk of cardiovascular events after discharge.For a variety of other cardiovascular diseases,including acute coronary syndrome and atrial fibrillation,will also lead to increased levels of natriuretic peptide.Therefore,BNP and NT-proBNP will be the active area of research in the clinic.
作者
王丹
韩翔宇
WANG Dan;HAN Xiangyu(School of Clinical Medicine,Jining Medical University,Jining 272067,China;不详)
出处
《中外医学研究》
2024年第24期175-178,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
山东省研究型医院协会科研项目(2022025)
山东省中医药科技项目(M-2022067)。
